focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Distribution agreement for Genesis products

16 Jul 2009 07:00

RNS Number : 7478V
Omega Diagnostics Group PLC
16 July 2009
 



AIM: ODX

Omega Diagnostics Group PLC ('Omega')

UK Distribution agreement for Genesis products 

Omega, the AIM listed medical diagnostics company, announces that its UK-based subsidiary, Genesis Diagnostics Ltd ('Genesis') has signed an exclusive distribution agreement with Biohit Healthcare Ltd ('Biohit'), the UK-based subsidiary of Biohit Oyj, a Finnish public company which develops, manufactures and markets liquid handling products and diagnostic test systems for use in research, health care and industrial laboratories.

Biohit will take on the UK distribution and servicing of the Genesis product range using their UK-wide sales force and will offer complete coverage of the UK NHS hospital network. Both companies are committed to maintaining and improving upon the high level of customer service provided by Genesis. Biohit already services many current Genesis customers and the customer base is expected to expand as a result of this agreement.

Andrew Shepherd, Chief Executive of Omega, said, "The synergy between Genesis and Biohit is clear in that both companies service the same clinical laboratory market with complementary products. The UK market for clinical diagnostic products is highly competitive and we need to have a full scale sales force that can operate across the UK and increase our business base going forward. Using Biohit provides us with access to a much enlarged customer base and allows our resources to be focussed on other growth areas in the UK and beyond."

 

Richard Vaughton, Managing Director of Biohit commented, "The addition of Genesis products enhances the offering to our current customer base and helps focus our sales drive in the clinical laboratory market. We look forward to providing an excellent service to existing Genesis customers, many of whom we are familiar with, and to winning many new customers."

Further enquiries:

Omega Diagnostics Group PLC:

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

Kieron Harbinson, Finance Director

www.omegadiagnostics.com

Cenkos Securities plc

Tel : 020 7397 8900

Nick Wells, Andy Roberts, Elizabeth Bowman

ebowman@cenkos.com

Walbrook PR Limited

Tel : 020 7933 8787

Paul McManus

Mob : 07980 541 893

paul.mcmanus@walbrookpr.com

Information on Biohit Oyj

Biohit Oyj, a Finnish Public company, develops, manufactures and markets liquid handling products and diagnostic test systems for use in research, health care and industrial laboratories.

Established in 1988, Biohit Oyj is headquartered in Finland. Biohit has subsidiaries in FranceGermany, the UKRussiaChinaJapan and the USA. Additionally, Biohit's products are sold by approximately 450 distributors in 70 countries. Biohit Oyj had net sales of 35.1M euros in 2008 and employed 370 personnel. 

Geographically sales are split as follows: Europe: 55.6%North & South America 18.1%Asia 11.5%Other Countries 14.8%

Biohit's shares (BIOBV) are quoted on NASDAQ OMX Helsinki. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRBLGDRBBBGGCU
Date   Source Headline
6th Sep 20237:00 amRNSAGM Statement
1st Sep 202310:29 amRNSUpdate on proposed Share Reorganisation
31st Aug 20237:00 amRNSProposed Share Reorganisation Timetable
22nd Aug 20237:00 amRNSDirectorate Change
17th Aug 20237:00 amRNSBoard Appointment
15th Aug 20231:45 pmRNSDirector/PDMR Shareholding
14th Aug 20237:00 amRNSPosting of Annual Report and confirmation of AGM
3rd Aug 20237:00 amRNSFinal Results
27th Jul 20237:00 amRNSNotice of Results
26th Jul 20232:10 pmRNSHolding(s) in Company
6th Jun 202311:19 amRNSHolding(s) in Company
5th Jun 20234:51 pmRNSHolding(s) in Company
2nd Jun 20232:45 pmRNSHolding(s) in Company
22nd May 20235:33 pmRNSHolding(s) in Company
10th May 20237:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
9th May 20233:42 pmRNSDirector/PDMR Shareholding
21st Apr 20239:48 amRNSHolding(s) in Company
19th Apr 20239:31 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSTrading Update
22nd Mar 20235:57 pmRNSBlock Listing Six Monthly Return
22nd Mar 20233:00 pmRNSHolding(s) in Company
6th Mar 20232:31 pmRNSHolding(s) in Company
27th Jan 20233:03 pmRNSHolding(s) in Company
27th Jan 20239:36 amRNSDirector/PDMR Shareholding
18th Jan 20237:00 amRNSTrading update
16th Jan 202310:56 amRNSHolding(s) in Company
6th Jan 20237:00 amRNSUS expansion update
3rd Jan 202312:34 pmRNSHolding(s) in Company
13th Dec 20224:40 pmRNSSecond Price Monitoring Extn
13th Dec 20224:35 pmRNSPrice Monitoring Extension
13th Dec 202212:01 pmRNSHolding(s) in Company
30th Nov 20229:35 amRNSHolding(s) in Company
25th Nov 20227:00 amRNSReceipt of deferred consideration
24th Nov 20227:00 amRNSHalf-year Report
23rd Nov 20224:41 pmRNSSecond Price Monitoring Extn
23rd Nov 20224:36 pmRNSPrice Monitoring Extension
23rd Nov 20222:05 pmRNSSecond Price Monitoring Extn
23rd Nov 20222:00 pmRNSPrice Monitoring Extension
18th Nov 202212:09 pmRNSHolding(s) in Company
16th Nov 20222:06 pmRNSSecond Price Monitoring Extn
16th Nov 20222:00 pmRNSPrice Monitoring Extension
15th Nov 20227:00 amRNSConfirmation of Results and Investor Presentation
14th Nov 20227:00 amRNSPartnership agreement with Software Provider
8th Nov 20229:04 amRNSLaunch of new all-employee share incentive plan
26th Oct 20222:50 pmRNSResult of AGM
26th Oct 20227:00 amRNSAGM Statement and Notice of Results
11th Oct 20227:00 amRNSScientific Director to present at FIDHC
5th Oct 20227:00 amRNSPositive WHO data received for VISITECT® CD4 test
27th Sep 20227:00 amRNSPosting of Annual Report and confirmation of AGM
20th Sep 202212:05 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.